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Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal-dominant disorder characterized by
predisposition to colorectal cancer and extracolonic malignancies, frequent multiple primary tumors in the
same patient, and early age of cancer onset. A main clinical variant of Lynch syndrome, Muir–Torre syndrome
(MTS) is characterized by the association between one or more visceral malignancies, with at least one
sebaceous skin tumor or keratoacanthoma. In our study, we have screened a cohort of 538 HNPCC patients,
related to 57 HNPCC families, to detect sebaceous skin tumors and keratoacanthomas and the role of mismatch
repair (MMR) genes, MLH1, MSH2, and MSH6, in their pathogenesis. Among the 57 HNPCC families, we have
identified four MTS families and one suspected MTS family, in which sebaceous carcinoma was found in one
HNPCC mutation carrier subject who did not show visceral malignancy. In four of these families, linked to two
MLH1 mutations and to two MSH2 mutations, biomolecular characterization showed concordance among
immunohistochemistry analysis and gene mutations. The evidences of our investigations show that MLH1 and
MSH2 gene mutations have an equivalent etiopathological role both for Lynch syndrome and for MTS; hence,
we propose a broadened clinical criteria for definition of Lynch syndrome that will include sebaceous adenoma,
carcinoma, and keratoacanthoma.
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INTRODUCTION
Hereditary non-polyposis colorectal cancer (HNPCC), also
referred to as Lynch syndrome, is an autosomal-dominant-
inherited disorder characterized by predisposition to colo-
rectal cancer and extracolonic malignancies (especially
endometrium, ovary, stomach, small bowel hepatobiliary
tract, uroepithelian tract, and brain), frequent multiple
primary tumors in the same patient, and early age of cancer
onset (Lynch and Lynch, 2005). The minimal clinical
requisites that should be satisfied for the diagnosis of Lynch
syndrome are defined by the ‘‘Amsterdam Criteria I’’ (Vasen
et al., 1991) and ‘‘Amsterdam Criteria II’’ (Vasen et al., 1999).
Successively, biomolecular parameters such as microsatellite
instability (MSI) have been included in Bethesda guidelines
(Rodriguez-Bigas et al., 1997) according to the evidences of
MSI in HNPCC related to colorectal cancer. Recently, a
revised Bethesda guidelines has modified the spectrum of
tumors that could be subjected to MSI analysis, including also
brain and some rare sebaceous skin tumors typically of
HNPCC variants (Umar et al., 2004). In fact, besides the
Turcot’s syndrome in which central nervous system malig-
nant tumors are reported (Hamilton et al., 1995), the other
main clinical variant of Lynch syndrome is the Muir–Torre
syndrome (MTS), which is characterized by the combination
of sebaceous gland tumors of the skin and internal
malignancies (Lynch et al., 1981). The MTS diagnosis is
based on the coexistence of at least one sebaceous skin tumor
(sebaceous adenomas and carcinomas) or keratoacanthoma
and one or more visceral malignancies (Schwartze and Torre,
1995). The most common internal malignancies is colorectal
cancer, accounting for 50% of all primary cancer in MTS;
another common site is the genitourinary tract but also
hematologic and breast malignancies are reported. The
recognition of rare sebaceous skin neoplasms is of crucial
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clinical relevance because it predicts the associated risk for
internal malignancies, thus giving rise to suspicion of a
hereditary mismatch repair (MMR) defect (Mangold et al.,
2004; Ponti et al., 2005a, b).
Lynch syndrome and MTS variants share common biomo-
lecular pathogenesis linked to MMR genes mutations (MLH1,
MSH2, MSH6, and PMS2) (Wheeler et al., 2000; Calvert and
Frucht, 2002). As a consequence of their inactivation, cells
show a generalized genome instability, which is particularly
evident at microsatellite loci (MSI) (Peltomaki et al., 1993;
Thibodeau et al., 1993). In particular, in MLH1 and MSH2
genes, the major proportion (80%) of pathogenetic mutation in
HNPCC families has been detected (Liu et al., 1996;
Papadopoulos and Lindblom, 1997). Muir–Torre phenotype
is not linked to particular biomolecular MMR genes alteration,
although the large majority of constitutional mutations are
found in MSH2 and only three MLH1 mutations are reported
linked to MTS phenotype (Mangold et al., 2004).
In this study, we have screened an HNPCC patients cohort
for the occurrence of sebaceous gland skin tumors and/or
keratoacanthomas for the recognitions and biomolecular
characterization of MTS. The specific aim of this study is to
clarify the role of MLH1 and MSH2 gene alterations in the
appearance of MTS phenotype and the relations between this
genodermatosis and Lynch syndrome.
RESULTS
We have searched for skin tumors typical of MTS disorder in
a cohort of 538 HNPCC patients belonging to 57 families
selected through Amsterdam criteria. Five HNPCC index
patients (about 1%) with diagnosis of sebaceous gland tumors
and/or keratoacanthomas were recognized. In one of them
(case 1), the diagnosis of sebaceous carcinoma was not
associated with visceral malignancies in the same patient,
although the family had typical HNPCC features: hence, we
have classified this HNPCC family as suspected MTS
(Figure 1). In the other four families, the patients responded
to criteria for MTS definition and had a diagnosis of
sebaceous skin lesions concomitantly (1) or successively
(4) to internal cancer development (Table 1).
The histologic diagnosis of skin lesions were: kerato-
acanthoma in one MTS family, and sebaceous adenomas,
epithelioma, and carcinoma in the other three MTS and
suspected MTS family. These skin lesions were, essentially,
localized on the eyelid and on the back. The mean age at first
diagnosis of skin tumors was 51.4 years. The mean age at
diagnosis of colorectal cancer was 51 years. In addition to
colorectal cancer, other visceral malignancies reported in
MTS families were uterus, ovary, pancreas, and breast cancer
(Table 1).
A total of four MMR genes constitutional mutations were
reported in the five MTS patients as a result of tumor tissue
analysis (Table 2). For all but one patient, we have examined
sebaceous skin tumors and keratoacanthomas for micro-
satellite status and immunohistochemical expression of MLH1,
MSH2, and MSH6 proteins. The skin lesions belonging to four
MTS probands showed MSI; moreover, in these cases, a
concordance with immunohistochemical analysis was found
(Figures 2 and 3). All visceral tumors in the MTS group have
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Figure 1. Genealogic three of suspected MTS linked to MSH2 mutations (del TT at 880 exo 5). A II-1 patient shows sebaceous carcinoma without visceral
malignancy.
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least one of the MMR proteins was evident in the same
patient. In three MTS patients, the evidences of immuno-
histochemistry (IHC) suggest the localization of a mutation in
MSH2/MSH6 gene (cases 1, 2, and 3) and in the other two
in MLH1 gene (cases 4 and 5).
The two MSH2 mutations were del TT at 880 exo 5 (case
1) and a large deletion at exo 1 (case 2). As regards case 3, no
other affected family members were available for segregation
analysis; IHC showed lack of MSH2 and MSH6 protein
expression and the tumor tissue was reported to be H-MSI
(Table 2). One of the two MLH1 mutations (case 4) was
characterized as founder mutations in four HNPCC families
distributed in the provinces of Modena and Reggio Emilia,
but in the patient belonging to the other three related families
with the same mutations, the appearance of sebaceous
lesions or keratoacanthomas was not reported. The mutation
consisted in the insertion of a T between nucleotides 2269
and 2270 (2269–2270 ins T), causing the synthesis of a longer
(by 33 amino acids) but unstable polypeptide (Caluseriu
et al., 2004). The other MLH1 mutation (case 5) was
c.1520–1521 ins T, causing a frameshift and appearance of
premature stop codons (Caluseriu et al., 2001).
Table 1. Clinical features of MTS patients identified among HNPCC families




in the proband (age)
Tumors in the
family (age)




2 M Sebaceous epithelioma 49 Back Colon 49 Rectum 59 (father)
Colon 38 (mother)




4 F Sebaceous adenoma 46 Eyelid Breast 38 Colon 33 (mother)
Uterus 40 Colon 39 (sister)
Colon 45 Colon 32 (brother)
Stomach 42 (uncle)
Colon 37 (uncle)
Uterus 50; colon 48 (ant)
Uterus 33 (grandmother)




F, female; HNPCC, hereditary non-polyposis colorectal cancer; M, male; MTS, Muir–Torre syndrome.
Figure 2. Immunohistochemical analysis of MMR proteins. (a) Lack of
expression of MLH1 protein in sebaceous carcinoma. (b) Lack of expression of
MSH2 protein in sebaceous carcinoma.
Figure 3. Clinical aspect of a keratoacanthoma in the MTS patient.
Bar¼10 mm; lesion size: 24 18 mm.
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DISCUSSION
The main evidence of our study was at first, a higher
incidence of rare sebaceous skin tumors and keratoacantho-
mas in the HNPCC subjects’ cohort with respect to the
general population and consequently the improvement of the
current clinical definition of this genetic disorder. The MTS
cases identified in our case histories of HNPCC families show
that the frequency of this phenotype is clearly underestimated
probably owing to the scarce importance assigned to research
and registering of sebaceous gland tumors and/or kerato-
acanthomas in personal and familiar anamnestic survey.
A clinical definition of MTS may result rather difficult as it
requires the coexistence of at least one sebaceous tumor or
keratoacancthoma with one or more visceral malignancy
(Schwartze and Torre, 1995); this clinical condition may
appear as sporadic MTS case in which a tumor family history
is not reported and as an allelic variant of Lynch syndrome,
for they share the same pathogenesis and similar clinical
features (Ponti and Ponz de Leon, 2005). However, we
believe that by including sebaceous tumors or keratoacantho-
mas in the clinical tumor spectrum of Lynch syndrome, the
supervision and investigation would be performed on very
small families whose full phenotype expression is difficult to
estimate and on visceral disease-free subjects, as in the
suspected MTS case examined herein (case 1). This approach
could be particularly useful for those cases in which a lack of
synchronous or metachronous coexistence in sebaceous
gland tumors and visceral malignancies in the same subject
would stop further mutational investigations and consequent
clinical surveillance.
The original Amsterdam criteria were created for the
necessity of homogenizing the cohort of colorectal cancer
families for multicenter clinical and biomolecular study
(Vasen et al., 1991). Their limitations and low efficacy in
the clinical applications were supplied by the Amsterdam
Criteria II (Vasen et al., 1999) that accounts in the clinical
tumors spectrum of HNPCC and other extracolonic tumors
such as endometrium, small bowel, ureter, or renal pelvis. In
the same way, the original Bethesda guidelines (Rodriguez-
Bigas et al., 1997), in which criteria for the selection of
colorectal tumors to be tested for MSI were present, has been
integrated by revised Bethesda guidelines including extra-
colonic HNPCC-associated tumors. Subsequently, sebaceous
gland adenomas and keratoacanthomas in MTS have been
included in the tumors to be tested for MSI (Umar et al.,
2004). Among these, we propose to include also rare
sebaceous carcinomas – that account for one in every 2,000
skin malignancies (Janjua et al., 1997) – as we believe that
these rare lesions should be tested even when they appear in
individuals without any visceral malignancies. Kruse et al.
(Kruse et al., 2003; Ponti et al., 2005a, b) suggested that to
every patient with a sebaceous tumor should be offered either
molecular genetic diagnostic or, if necessary, a strict regular
cancer surveillance program. These rare sebaceous lesions
will have to be researched and registered especially in
HNPCC contests where MTS may form a variant.
The MTS tumors spectrum is well defined for the peculiar
skin tumor, but some contentions exist about visceral tumor
spectrum. In fact, with the exception of colorectal and
urogenital cancers (Davis and Cohen, 1995; Ponti and Ponz
de Leon, 2005), the role of other visceral malignancies needs
further investigations, such as for the breast cancer that seems
to be frequently reported among MTS-associated neoplasms
(Cohen et al., 1995). Although breast cancer has been
occasionally reported in the HNPCC pedigree (Risinger et al.,
1992), several investigations show that it may represent
phenocopies unrelated to the presence of MMR gene
mutations (Anbazhagan et al., 1999; Aarnio et al., 1999;
Vasen et al., 1999; Caluseriu et al., 2001).
The geno-phenotype characterization in MTS and sus-
pected MTS cases shows that MLH1 and MSH2 have an
equivalent etiopathological role and that there is no correla-
tion between MTS mutations and particular functional
domains inside these two genes. Therefore, the ‘‘subordi-
nate’’ role of MLH1 in the MTS genesis has to be re-evaluated
and its involvement should always be investigated, together
with MSH2, first through IHC analysis, and second through
direct sequencing or deletion mapping. On the other hand, it
seems rather unclear how, under the same mutation and
family history, a MTS phenotype appears only in some cases:
for instance, the MLH1 founder case shows that the same
mutation associated to phenotype MTS in our index patient
does not match with such phenotype in other carriers of the
same mutation, either in the same family or in other HNPCC-
correlated families. These evidences could be owing to lower
penetrance of MLH1 mutations with respect to MSH2
mutations that are usually reported to convey a higher risk
for extracolonic cancer than MLH1 (Hampel et al., 2005).
Table 2. Biomolecular features of MTS patients identified among HNPCC families
Case Sex MSI IHC Mutation analysis
1 F H-MSI Lack of expression of MSH2/MSH6 del TT at 880 exo 5 of hMSH2
2 M H-MSI Lack of expression of MSH2/MSH6 Large deletion exo 1 of hMSH2
3 M H-MSI Lack of expression of MSH2/MSH6 Not tested (proband deceased)
4 F H-MSI Lack of expression of MLH1 ins T 2269–2270 of hMLH1
5 F H-MSI Lack of expression of MLH1 c.1520–1521 ins T of hMLH1
F, female; HNPCC, hereditary non-polyposis colorectal cancer; IHC, immunohistochemistry; M, male; MSI, microsatellite instability; MTS, Muir–Torre
syndrome.
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Hence, further studies are needed to investigate thoroughly
the relationship between the cutaneous cancerogenesis and
the molecular alterations owing to MMR genes and their
genomic instability, in particular for the cases of ‘‘founder
mutations’’ inherited. Such as for the Lynch syndrome
(Peltomaki and Vasen, 2004), even in MTS the known
founder mutations could be first tested by IHC analysis in all
sebaceous lesions or multiple keratoacanthomas, registered
in the specific area potentially linked to ‘‘founder mutation
effects’’.
Although the current definition of MTS identifies sporadic
cases accurately, it does not include all those relevant family
characteristics in MTS allelic variant of HNPCC; therefore,
an additional ‘‘broadened’’ clinical definition of Lynch syn-
drome, including also sebaceous skin tumors and kerato-
acanthomas in the neoplastic spectrum, should be provided.
The molecular pathogenesis of the syndrome is caused by
both MSH2 and MLH1, and whenever the tumor tissue shows
MSI, this gene shall be investigated together with MSH2. In
this way, also when associated visceral malignancies are
absent, the mutational analysis in first-degree relatives of
gene carriers may be directed to the isolation of the sole cut
phenotype, so that the mutational research in these subjects
may anticipate all those prevention strategies applied to
visceral associated risk.
MATERIALS AND METHODS
The study was conducted according to the Declaration of Helsinki
Principles and institutional approval and written informed patient
consent were obtained.
HNPCC families
Screening for sebaceous gland tumors and keratoacanthoma was
performed in 538 HNPCC patients identified from the data of
specialized registry that was instituted in 1984 in the District of
Modena (Northen Italy) (Ponz de Leon et al., 1999) and through
references from other areas of Italy. Since then, a total of 57 kindred
with clinical features of HNPCC have been collected, and in 25 of
them, germline mutations in MLH1, MSH2, and MSH6 are reported.
All the HNPCC families fulfilled the diagnostic Amsterdam I or
Amsterdam II criteria for HNPCC definition.
MSI analysis
Paraffin-embedded tumor tissue and corresponding normal mucosa
were microdissected with sterile scalpels into polypropylene tubes.
The tumor and normal tissue were deparaffined with xylene, washed
with ethanol, and dried up. The digestion was performed at 501C
overnight. The samples were then heated at 801C for 10 minutes to
inactivate the proteinase K and centrifuged. After purification with
NaCl-saturated solution and precipitation in absolute ethanol, the
supernatant was used as template for PCR amplification. MSI status
was determined by using five fluorescent-labelled microsatellite
markers (BAT25, BAT26, D2S123, D5S346, and D17S250, the
Bethesda Panel). PCR reactions were carried out in a 10 ml reaction
volume containing 50–100 ng of genomic DNA, 0.15 pmol of dye-
labelled forward and unlabelled reverse primers, 2 mM concentration
of each deoxynucleotide triphosphate, 1.5 mM MgCl2, 50 mM KCl,
10 mM Tris (pH 8.3), and 0.6 U of Taq polymerase. PCR products
were run on a CEQ 8000 Sequencer (Beckman Coulter, Milano,
Italy), and analyzed using the Fragment Analysis System by Beckman
Coulter. Lesions were scored as MSIþ when instability could be
detected in at least two microsatellite loci. A family was considered
MSIþ when 50% or more of the investigated patients showed MSI in
the researched neoplasms.
IHC analysis
Immunohistochemical analysis of MSH6, MLH1, and MSH2 proteins
were carried out on paraffin-embedded tumor samples. Immuno-
peroxidase staining, using diaminobenzidine as chromogen, was run
with the NEX-ES Automatic Staining System (Ventana, Strasbourg,
France). Mouse mAbs were anti-MSH6 (Transduction Labs, BD
Biosciences, Milano, Italy) at 1:2,000 dilution, anti-MLH1 (Pharmin-
gen, San Diego, CA) at 1:40 dilution, and anti-MSH2 (Pharmingen)
at 1:40 dilution. Nuclei were counterstained with hematoxylin and
adjacent normal tissue in each sample served as positive control.
Mutation analysis
The study of germline mutations in the main DNA MMR genes
(MLH1, MSH2, and MSH6) were performed by direct genomic
sequencing of DNA derived from blood leukocytes of the proband or
other affected family members. Amplification products were
generated with primers located in the flanking introns approximately
50 bp from the respective intron/exon borders to detect all possible
splice junction mutations. The sequences were determined on a CEQ
8000 Sequencer (Beckman Coulter) and analyzed with the Sequence
Analysis System by Beckman Coulter. At the beginning of the study,
germline mutations of MMR genes were evaluated under previously
reported conditions (Caluseriu et al., 2004).
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